EyePoint Pharmaceuticals has received stockholder approval for a second tranche of growth capital under a securities purchase agreement with Essex Woodland Healthcare Partners and Rosalind Advisors, according to a press release.
Gross proceeds, which includes $9.5 million from the March 2018 equity financing with EW Healthcare Partners, will total $35 million upon closing, the release said. In addition, the company will draw an additional $5 million under its existing credit agreement with SWK Funding LLC, and assuming full exercise of the warrants, total gross proceeds will come to $60.5
Uncategorized